Liver Glycotargeting of Antiviral Nucleoside Analogues.

Antiviral activity of nucleoside analogues against norovirus.

BACKGROUND Norovirus (NoV) is the leading cause of epidemic gastroenteritis worldwide. The lack of a cell culture has significantly hampered the development of effective therapies against human NoV. Clinically approved nucleoside and non-nucleoside analogues have been used successfully against RNA viruses. METHODS In this study, we evaluated the efficacy of four nucleoside analogues (2'-C-MeC...

Antiviral Activity of 5-substituted Pyrimidine Nucleoside Analogues

From a large series of 5—substituted 1—(2—deoxy——D—ribofuranosyl)—ura— cil (dUrd) , 1—(2—deoxy——D—ribofuranosyl)—cytosine (dCyd) and 1—(—D—arabinofurano— syl)—uracil (araU) analogues that have been evaluated for their antiviral proper— ties, the (E)—5—(2—bromovinyl)derivatives emerged as the most potent and most selec— tive antiherpes agents. (E)—5—(2—Bromovinyl)—dUrd (BVDU) and its congeners, ...

Chemical Synthesis of Nucleoside Analogues Chemical Synthesis of Nucleoside Analogues

Synthesis Optimization of Some Nucleoside Analogues Derivatives and Their Antiviral Activity

To prepare the target nucleosides, the branched chain sugars was converted to their active form (1-bromosugar derivatives). This conversion included the hydrolysis of bromination with hydrobromic acid (HBr) in glacial acetic acid, forming 1-bromo sugars (4,6-di-O-Acetyl-2,3-dideoxy-3,3-di-C-nitro methyl-Darabinohexopyranosyl bromide), which were subjected to condensation with theophylline mercu...

Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B

BACKGROUND Off-treatment durability of nucleoside analogue (NA) therapy in patients with chronic hepatitis B has not been well investigated. In this study we monitored antiviral effect of NA therapy and evaluated off-treatment durability after NA cessation in patients with chronic hepatitis B. PATIENTS AND METHODS A total of 94 consecutive patients (39 HBeAg-negative and 55 HBeAg-positive pat...